EUCTR2016-002743-41-DE进行中（未招募）1 期
Prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial to evaluate the efficacy and safety of cineole vs. placebo in the treatment of acute non-purulent rhinosinusitis - Cineole in acute non-purulent rhinosinusitis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Subjects who are able to understand and are willing to comply to trial instructions.
- •2)Having given written informed consent.
- •3)Age 18 to 75 years (inclusively).
- •4)Diagnosis of acute non-purulent rhinosinusitis with an appearance of sinusitis symptoms
- •= 5 days confirmed by ultrasonography of paranasal sinuses.
- •5)Baseline investigator-evaluated major symptom score (MSS) of =8 and =12
- •(of maximal 15 score points), out of the 5 main rhinosinusitis symptoms at least 3 must be present. Among these the presence of nasal congestion and facial pain / pressure is mandatory.
- •6)Presence of nasal congestion (score of = 1 on four-point rating scale).
- •7)Mild to moderate facial pain/pressure (score of = 1 and = 2 on four-point rating scale).
- •8)Satisfactory health condition except for the rhinosinusitis as determined by the investigator based on medical history and physical examination.
- •9)No clinical assumption of necessity for antibiotic indication or application within 3 days before treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 235
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1)Clinical assumption of necessity for antibiotic indication or application within 3 days before treatment.
- •2)History of hypersensitivity to any excipient of the applied drugs.
- •3)Concomitant treatment with antibiotics, decongestal nasal sprays, antacida and proton-pump inhibitors, secretolytic agents other than the trial medication or any other medication or treatment listed in the disallowed medication list.
- •4)Acute exacerbation of allergic or chronic rhinosinusitis within 30 days.
- •5)Surgery of paranasal sinuses within 6 weeks.
- •6)Polyposis nasi, Cystic fibrosis and anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation / airflow.
- •7)Patients with bronchial asthma.
- •8)Underlying diseases leading to significant immune deficiency.
- •9)Signs or symptoms of fulminant bacterial sinusitis (e.g. fever > 38.5 °C, orbital complications, severe unilateral frontal headache or toothache).
- •10)Odontogenic sinusitis.
- •11)Drug or alcohol abuse in the opinion of the investigator.
- •12)Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly.
- •13)Pregnant or nursing (lactating) women.
- •14)Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as:
- •Surgical sterilization
- •Hormonal contraception
- •Total abstinence throughout the trial at the discretion of the investigator
- •Periodic abstinence is NOT an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the trial.
- •A woman who is post-menopausal must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of child-bearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •15)Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject’s ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease.
- •16)Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.
- •17) Subject is in custody by order of an authority or a court of law.
- •18)Subjects with chronic obstructive pulmonary disease (COPD), pertussis or pseudocroup.
研究者
相似试验
招募中
4 期
Prospective, randomized, double-blind, placebo-controlled, multicenter clinical investigation to determine the clinical performance and safety of Luvos® Healing Earth in patients with histamine-mediated recurrent digestive symptoms.T78.1T62K58K59Other adverse food reactions, not elsewhere classifiedToxic effect of other noxious substances eaten as foodOther functional intestinal disordersIrritable bowel syndromeDRKS00027333Heilerde-Gesellschaft Luvos Just GmbH % Co. KG114
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityChronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescentsMedDRA version: 18.0Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004532-30-Outside-EU/EEAMerz Pharmaceuticals GmbH249
进行中（未招募）
1 期
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityEUCTR2013-004532-30-HUMerz Pharmaceuticals GmbH249
进行中（未招募）
1 期
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injuryMedDRA version: 20.0Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2018-001639-35-ITMerz Pharmaceuticals GmbH600
进行中（未招募）
1 期
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injuryMedDRA version: 21.1Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2018-001639-35-CZMerz Pharmaceuticals GmbH600